The U.S. Food and Drug Administration (FDA) is considering comments to their risk-focused draft guidance, “Laser-Assisted In Situ Keratomileusis (LASIK) Lasers-Patient Labeling Recommendations.” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback